Dexmedetomidine Versus Sevoflurane in Children With Anticipated Difficult Intubation

NCT04426552 — Phase 2, Unknown, 40 participants, Alexandria University

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

Dexmedetomidine Versus Sevoflurane Inhalation for Fibreoptic Nasotracheal Intubation in Children With Anticipated Difficult Intubation

RegistryNCT04426552
StatusUnknown
PhasePhase 2
Study typeInterventional; randomized, parallel, masking: single, diagnostic
Enrollment40 (Estimated)
SponsorAlexandria University (Other)
ConditionsCraniofacial Abnormalities, Mandibular Hypoplasia
Interventionsdexmedetomidine, sevoflurane (Drug)
Datesstart 2020-06-01, primary completion 2020-09-20 (estimated), completion 2020-10-20 (estimated), first posted 2020-06-11, last updated 2020-06-12
Locations1 site in Egypt

Related Papers Related Patents Related Grants Related Experts
All trials for Craniofacial Abnormalities All trials for Mandibular Hypoplasia All trials of dexmedetomidine All trials of sevoflurane

-Summary

difficult problem in the paediatric age group because of their small mouth opening and un-cooperativeness.Currently used methods of sedation for fibreoptic intubation such as benzodiazepines, propofol or opioids may cause respiratory depression, especially when used in high doses

Expand all sections  ·  Collapse all

+Detailed description

Dexmedetomidine, an a2-agonist, has none-to-minimal respiratory depressant effects, which is clearly a great advantage in handling a critical (unstable, difficult) airway while inducing sedation in both adult and infants. The aim is to compare intubation conditions between dexmedetomidine and sevoflurane inhalation during fibreoptic intubation in pediatric patients with an anticipated difficult intubation

+Arms and interventions

ArmTypeInterventionsDescription
DexmedetomidineExperimentalDrug: dexmedetomidinehave a bolus of dexmedetomidine one μg/kg (Precedex; Hospira, Inc, Lake Forest, IL) administered for 10 minutes, followed by a continuous infusion at 0.7 μg • kg-1 • h-1 during FOI
SevofluraneActive comparatorDrug: sevoflurane(sevoflurane) will be preoxygenated using face mask with 100% oxygen for 3 min to increase oxygen reserve and then inhalational induction will be started with sevoflurane in 100% oxygen using Ayre's piece circuit/MapelsonD circuit according to age and weight of the patient while performing fiberoptic intubation
  • dexmedetomidine (Drug): will have a bolus of dexmedetomidine one μg/kg (Precedex; Hospira, Inc, Lake Forest, IL) administered for 10 minutes, followed by a continuous infusion at 0.7 μg • kg-1 • h-1 during FOI
  • sevoflurane (Drug): preoxygenated using face mask with 100% oxygen for 3 min to increase oxygen reserve and then inhalational induction will be started with sevoflurane in 100% oxygen using Ayre's piece circuit/MapelsonD circuit according to age and weight of the patient while performing fiberoptic intubation

+Outcome measures

Primary outcomes

  • Assessment of intubation [At intubation time]: as assessed by vocal cord movement

+Eligibility

Sex: All, ages: 1 Year to 3 Years

Inclusion Criteria:

* ASA physical status I and II
* aged 1 year to 3 years
* require general anaesthesia with tracheal intubation for surgical correction of the congenital or acquired pathology that created the difficult airway

Exclusion Criteria:

* parents refusal
* Allergy to drugs

+Locations (1)

FacilityCityCountryStatus
Rehab Abd Elraof Abd ElazizAlexandria, SmouhaEgyptRecruiting

+Investigators